Quercetin inhibits the growth of triple-negative breast cancer via the AKT1 pathway
This study demonstrates that quercetin inhibits triple-negative breast cancer progression by directly binding to and suppressing AKT1 phosphorylation, thereby blocking β-catenin nuclear translocation and inducing apoptosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Breast cancer is a complex disease, but one of its most dangerous forms is known as triple-negative breast cancer. This specific type is difficult to treat because the cancer cells lack three common receptors that doctors usually target with standard therapies. As a result, patients often rely on chemotherapy, which can be harsh and sometimes fails to stop the disease from returning or spreading. In the search for gentler, more effective treatments, scientists frequently look to nature, examining compounds found in plants that might stop cancer cells from growing without causing severe harm to the rest of the body. One such compound is quercetin, a natural substance found in many fruits and vegetables that has long been studied for its ability to fight inflammation and protect cells. While researchers have known for some time that quercetin can slow down cancer growth, the exact way it works inside the body has remained a mystery. Understanding the precise mechanism is crucial, because knowing how a drug works allows scientists to predict its effects and develop better treatments for patients who have few other options.
A team of researchers at the University of Science and Technology of China set out to solve this puzzle by focusing on triple-negative breast cancer. They wanted to find out exactly how quercetin stops these cancer cells from multiplying and whether it targets a specific part of the cell's internal machinery. To do this, they grew human triple-negative breast cancer cells in a laboratory and treated them with different amounts of quercetin. They observed that the compound significantly slowed down the growth of the cells and caused many of them to die off naturally, a process known as apoptosis. This was a clear sign that quercetin was effective, but the researchers needed to know which internal switch the compound was flipping to cause this result.
To identify the target, the scientists analyzed the genetic activity of the treated cells. They looked at thousands of genes to see which ones changed their behavior after exposure to quercetin. This analysis pointed them toward a specific protein called AKT1. In healthy cells, AKT1 helps regulate growth and survival, but in many cancers, it becomes overactive, acting like a stuck accelerator that drives the tumor to grow and spread. The researchers found that in patients with triple-negative breast cancer, high levels of AKT1 were linked to a poorer outlook for survival. When they treated the cancer cells with quercetin, the levels of the active form of this protein dropped significantly. This suggested that quercetin was directly interfering with AKT1, effectively taking the foot off the accelerator.
To confirm that quercetin was physically binding to this protein, the team used several different methods. They created a molecular model to see how the two fit together, which showed that quercetin could nestle into a specific pocket on the AKT1 protein, forming strong chemical bonds. They then tested this in the lab using a technique that measures how stable a protein is when heated. Normally, proteins break down when they get hot, but when quercetin was attached to the protein, it held its shape at higher temperatures, proving a direct physical connection. They also used a probe to pull the protein out of a mixture of cell contents, and quercetin successfully grabbed onto AKT1. These experiments confirmed that quercetin does not just happen to affect the cell; it specifically targets and binds to the AKT1 protein.
The study went further to explain what happens after this binding occurs. The researchers discovered that when AKT1 is active, it helps another molecule, called beta-catenin, move into the center of the cell, where it tells the cell to keep dividing. By binding to AKT1, quercetin stops it from working, which prevents beta-catenin from entering the cell's command center. Without this signal, the cancer cells stop growing and begin to die. The team also tested this relationship by artificially increasing the amount of AKT1 in the cells. When they did this, the cancer cells became resistant to quercetin and continued to grow, proving that AKT1 is indeed the key target. Conversely, when they reduced the amount of AKT1, the cells became even more sensitive to the treatment.
While the findings are promising, the researchers note that these results come from laboratory experiments using cells in a dish. The study demonstrates a clear chain of events: quercetin binds to AKT1, stops the protein from activating, prevents a growth signal from entering the cell's nucleus, and ultimately kills the cancer cells. The work provides a solid foundation for understanding how a natural compound can fight a difficult type of cancer, but the authors emphasize that further testing in living organisms is needed to see if these results hold true in patients. For now, the study offers a detailed map of how quercetin works at a molecular level, turning a vague idea of "natural healing" into a specific, testable mechanism that could guide future drug development.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.